The path from TB diagnostic development to rollout and uptake necessarily involves multiple stakeholders and partners to achieve impact. Stakeholders are listed according to their primary role. If you notice your group or any other group missing from this list, please send us the name of the organization or group, their primary role, and their web address, and we will be happy to include it. 

Donor/Funding Agency


Unitaid is an international organisation that invests in new ways to prevent, diagnose and treat HIV/AIDS, tuberculosis and malaria more quickly, more cheaply and more effectively. Unitaid is a hosted partnership of the World Health Organization (WHO). Unitaid researches and identifies new health solutions with potential to alleviate the burden of HIV/AIDS, tuberculosis and malaria. Through calls for proposals, they find partners best qualified to put key innovations into practice. These partners receive grants from Unitaid to fast-track access and reduce costs of more effective medicines, technologies and systems. In this way, Unitaid’s investments establish the viability of health innovations, allowing partner organisations to make them widely available.


Product Development Partnership

Foundation for Innovative New Diagnostics (FIND)

The Foundation for Innovative New Diagnostics, or FIND, is an international non-profit organization that enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola.

FIND acts as a bridge between experts in technology development, policy and clinical care, reducing barriers to innovation and effective implementation of diagnostic solutions in low- and middle-income countries.


Implementation/Technical Assistance Partner

European-Latin American-Caribbean-Tuberculosis (EurolacTB) Consortium

EurolacTB is a consortium aimed at promoting and strengthening research collaboration between European and Latin American scientists in the area of tuberculosis.

Stop TB Partnership

The Stop TB Partnership is leading the way to a world without tuberculosis (TB), a disease that is curable but still kills three people every minute. Founded in 2001, the Partnership's mission is to serve every person who is vulnerable to TB and ensure that high-quality diagnosis, treatment and care is available to all who need it. They operate through a secretariat hosted by UNOPS in Geneva, Switzerland and seven working groups whose role is to accelerate progress on access to TB diagnosis and treatment; research and development for new TB diagnostics, drugs and vaccines; and tackling drug resistant- and HIV-associated TB. The secretariat is governed by a Coordinating Board that sets strategic direction for the global fight against TB. The Partnership is recognized as a unique international body with the power to align actors all over the world in the fight against TB. The participation of a wide range of constituencies gives us credibility and the broad range of medical, social and financial expertises needed to defeat TB.


Academic TB Group

McGill International TB Centre

The McGill International TB Centre, situated at the McGill University Health Centre in Montreal, Canada, is a world leader in the interdisciplinary study of TB, bringing together researchers in biomedical, clinical, epidemiological and social determinants of TB and other mycobacterial diseases.

Pai Global TB Group

Prof. Madhukar Pai, MD, PhD is a Canada Research Chair in Epidemiology & Global Health at McGill University, Montreal. He is the Director of McGill Global Health Programs, and Associate Director of the McGill International TB Centre. Madhu’s research is mainly focused on improving the diagnosis and treatment of tuberculosis, especially in high-burden countries like India and South Africa. His research is supported by grant funding from the Gates Foundation, Grand Challenges Canada, and Canadian Institutes of Health Research. He has more than 300 publications. He is recipient of the Union Scientific Prize, Chanchlani Global Health Research Award, and Haile T. Debas Prize. He is a member of the Royal Society of Canada.


Advocacy Group

Treatment Action Group (TAG)

Treatment Action Group (TAG) is an independent, activist and community-based research and policy think tank fighting for better treatment, prevention, a vaccine, and a cure for HIV, tuberculosis, and hepatitis C virus.


Regulatory Agency

World Health Organization

The World Health Organization (WHO) is the directing and coordinating authority on international health within the United Nations’ system. Among the many areas of work, WHO's efforts in TB diagnostics include: Target product profile development and consensus building among stakeholders; industry engagement at early stages of development with guidance on preliminary assessment; study design and evaluation protocols for new technologies; commissioning systematic reviews of available studies for WHO review; GRADE evaluation of new diagnostics for potential endorsement; and supporting country adoption and dissemination of guidance on different technologies.